Cargando…

Using Pharmacokinetic Modeling and Electronic Health Record Data to Predict Clinical and Safety Outcomes after Methylprednisolone Exposure during Cardiopulmonary Bypass in Neonates

BACKGROUND: Infants undergoing cardiac surgery with cardiopulmonary bypass (CPB) frequently receive intraoperative methylprednisolone (MP) to suppress CPB-related inflammation; however, the optimal dosing strategy and efficacy of MP remain unclear. METHODS: We retrospectively analyzed all infants un...

Descripción completa

Detalles Bibliográficos
Autores principales: Foote, Henry P., Wu, Huali, Balevic, Stephen J., Thompson, Elizabeth J., Hill, Kevin D., Graham, Eric M., Hornik, Christoph P., Kumar, Karan R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361697/
https://www.ncbi.nlm.nih.gov/pubmed/37484782
http://dx.doi.org/10.32604/chd.2023.026262
_version_ 1785076268173099008
author Foote, Henry P.
Wu, Huali
Balevic, Stephen J.
Thompson, Elizabeth J.
Hill, Kevin D.
Graham, Eric M.
Hornik, Christoph P.
Kumar, Karan R.
author_facet Foote, Henry P.
Wu, Huali
Balevic, Stephen J.
Thompson, Elizabeth J.
Hill, Kevin D.
Graham, Eric M.
Hornik, Christoph P.
Kumar, Karan R.
author_sort Foote, Henry P.
collection PubMed
description BACKGROUND: Infants undergoing cardiac surgery with cardiopulmonary bypass (CPB) frequently receive intraoperative methylprednisolone (MP) to suppress CPB-related inflammation; however, the optimal dosing strategy and efficacy of MP remain unclear. METHODS: We retrospectively analyzed all infants under 90 days-old who received intra-operative MP for cardiac surgery with CPB from 2014–2017 at our institution. We combined real-world dosing data from the electronic health record (EHR) and two previously developed population pharmacokinetic/pharmacodynamic models to simulate peak concentration (Cmax) and area under the concentration-time curve for 24 h (AUC24) for MP and the inflammatory cytokines interleukin-6 (IL-6) and interleukin-10 (IL-10). We evaluated the relationships between post-operative, safety, and other clinical outcomes obtained from the EHR with each predicted exposure using non-parametric tests. RESULTS: A total of 142 infants with median post-natal age 8 (interquartile range [IQR]: 5, 37) days received a total dose of 30 (19, 49) mg/kg of MP. Twelve (8%) died, 37 (26%) met the composite post-operative outcome, 114 (80%) met the composite safety outcome, and 23 (16%) had a major complication. Predicted median Cmax and AUC24 IL-6 exposure was significantly higher for infants meeting the composite post-operative outcome and those with major complications. Predicted median Cmax and AUC24 MP exposure was significantly higher for infants requiring insulin. No exposure was associated with death or other safety outcomes. CONCLUSIONS: Pro-inflammatory IL-6, but not MP exposure, was associated with post-operative organ dysfunction, suggesting current MP dosing may not adequately suppress IL-6 or increase IL-10 to impact clinical outcomes. Prospective study will be required to define the optimal exposure-efficacy and exposure-safety profiles in these infants.
format Online
Article
Text
id pubmed-10361697
institution National Center for Biotechnology Information
language English
publishDate 2023
record_format MEDLINE/PubMed
spelling pubmed-103616972023-07-21 Using Pharmacokinetic Modeling and Electronic Health Record Data to Predict Clinical and Safety Outcomes after Methylprednisolone Exposure during Cardiopulmonary Bypass in Neonates Foote, Henry P. Wu, Huali Balevic, Stephen J. Thompson, Elizabeth J. Hill, Kevin D. Graham, Eric M. Hornik, Christoph P. Kumar, Karan R. Congenit Heart Dis Article BACKGROUND: Infants undergoing cardiac surgery with cardiopulmonary bypass (CPB) frequently receive intraoperative methylprednisolone (MP) to suppress CPB-related inflammation; however, the optimal dosing strategy and efficacy of MP remain unclear. METHODS: We retrospectively analyzed all infants under 90 days-old who received intra-operative MP for cardiac surgery with CPB from 2014–2017 at our institution. We combined real-world dosing data from the electronic health record (EHR) and two previously developed population pharmacokinetic/pharmacodynamic models to simulate peak concentration (Cmax) and area under the concentration-time curve for 24 h (AUC24) for MP and the inflammatory cytokines interleukin-6 (IL-6) and interleukin-10 (IL-10). We evaluated the relationships between post-operative, safety, and other clinical outcomes obtained from the EHR with each predicted exposure using non-parametric tests. RESULTS: A total of 142 infants with median post-natal age 8 (interquartile range [IQR]: 5, 37) days received a total dose of 30 (19, 49) mg/kg of MP. Twelve (8%) died, 37 (26%) met the composite post-operative outcome, 114 (80%) met the composite safety outcome, and 23 (16%) had a major complication. Predicted median Cmax and AUC24 IL-6 exposure was significantly higher for infants meeting the composite post-operative outcome and those with major complications. Predicted median Cmax and AUC24 MP exposure was significantly higher for infants requiring insulin. No exposure was associated with death or other safety outcomes. CONCLUSIONS: Pro-inflammatory IL-6, but not MP exposure, was associated with post-operative organ dysfunction, suggesting current MP dosing may not adequately suppress IL-6 or increase IL-10 to impact clinical outcomes. Prospective study will be required to define the optimal exposure-efficacy and exposure-safety profiles in these infants. 2023 2023-06-09 /pmc/articles/PMC10361697/ /pubmed/37484782 http://dx.doi.org/10.32604/chd.2023.026262 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Foote, Henry P.
Wu, Huali
Balevic, Stephen J.
Thompson, Elizabeth J.
Hill, Kevin D.
Graham, Eric M.
Hornik, Christoph P.
Kumar, Karan R.
Using Pharmacokinetic Modeling and Electronic Health Record Data to Predict Clinical and Safety Outcomes after Methylprednisolone Exposure during Cardiopulmonary Bypass in Neonates
title Using Pharmacokinetic Modeling and Electronic Health Record Data to Predict Clinical and Safety Outcomes after Methylprednisolone Exposure during Cardiopulmonary Bypass in Neonates
title_full Using Pharmacokinetic Modeling and Electronic Health Record Data to Predict Clinical and Safety Outcomes after Methylprednisolone Exposure during Cardiopulmonary Bypass in Neonates
title_fullStr Using Pharmacokinetic Modeling and Electronic Health Record Data to Predict Clinical and Safety Outcomes after Methylprednisolone Exposure during Cardiopulmonary Bypass in Neonates
title_full_unstemmed Using Pharmacokinetic Modeling and Electronic Health Record Data to Predict Clinical and Safety Outcomes after Methylprednisolone Exposure during Cardiopulmonary Bypass in Neonates
title_short Using Pharmacokinetic Modeling and Electronic Health Record Data to Predict Clinical and Safety Outcomes after Methylprednisolone Exposure during Cardiopulmonary Bypass in Neonates
title_sort using pharmacokinetic modeling and electronic health record data to predict clinical and safety outcomes after methylprednisolone exposure during cardiopulmonary bypass in neonates
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361697/
https://www.ncbi.nlm.nih.gov/pubmed/37484782
http://dx.doi.org/10.32604/chd.2023.026262
work_keys_str_mv AT footehenryp usingpharmacokineticmodelingandelectronichealthrecorddatatopredictclinicalandsafetyoutcomesaftermethylprednisoloneexposureduringcardiopulmonarybypassinneonates
AT wuhuali usingpharmacokineticmodelingandelectronichealthrecorddatatopredictclinicalandsafetyoutcomesaftermethylprednisoloneexposureduringcardiopulmonarybypassinneonates
AT balevicstephenj usingpharmacokineticmodelingandelectronichealthrecorddatatopredictclinicalandsafetyoutcomesaftermethylprednisoloneexposureduringcardiopulmonarybypassinneonates
AT thompsonelizabethj usingpharmacokineticmodelingandelectronichealthrecorddatatopredictclinicalandsafetyoutcomesaftermethylprednisoloneexposureduringcardiopulmonarybypassinneonates
AT hillkevind usingpharmacokineticmodelingandelectronichealthrecorddatatopredictclinicalandsafetyoutcomesaftermethylprednisoloneexposureduringcardiopulmonarybypassinneonates
AT grahamericm usingpharmacokineticmodelingandelectronichealthrecorddatatopredictclinicalandsafetyoutcomesaftermethylprednisoloneexposureduringcardiopulmonarybypassinneonates
AT hornikchristophp usingpharmacokineticmodelingandelectronichealthrecorddatatopredictclinicalandsafetyoutcomesaftermethylprednisoloneexposureduringcardiopulmonarybypassinneonates
AT kumarkaranr usingpharmacokineticmodelingandelectronichealthrecorddatatopredictclinicalandsafetyoutcomesaftermethylprednisoloneexposureduringcardiopulmonarybypassinneonates